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Pyoderma gangrenosum (PG) is an important disease with significant complications. The objectives of this study
were to determine incidence and mortality of PG and strength of reported associations. A retrospective cohort
study was completed using computerized medical records from the General Practice Research Database, a large
representative UK database. Patients with PG and three groups of age-, sex-, and practice-matched controls—
general population, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) controls—were included
in the study. Incidence and mortality were determined and validation undertaken to inform diagnostic accuracy.
In all there were 313 people with the median age of 59 (interquartile range 41–72) years, and of them 185 (59%)
were female. The adjusted incidence rate standardized to European standard population was 0.63
(95% confidence interval (CI) 0.57–0.71) per 100,000 person-years. The risk of death was three times higher
than that for general controls (adjusted hazard ratio¼ 3.03, 95% CI 1.84–4.73, Po0.001), 72% higher than that for
IBD controls (adjusted hazard ratio¼ 1.72, 95% CI 1.17–2.59, P¼ 0.013), with a borderline increase compared with
RA controls (adjusted hazard ratio¼ 1.55, 95% CI 1.01–2.37, P¼ 0.045). Disease associations were present in 110
(33%) participants: IBD, n¼ 67 (20.2%); RA, n¼ 39 (11.8%); and hematological disorders, n¼ 13 (3.9%). To our
knowledge, there are no previous population-based studies of the epidemiology of PG, an important disease
with significantly increased mortality.
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INTRODUCTION
Pyoderma gangrenosum (PG) is a rare ulcerative neutrophilic
condition usually affecting the skin, with rare extracutaneous
involvement. The pathogenesis of PG is poorly understood.
This disorder requires intensive multidisciplinary manage-
ment, involving dermatologists, plastic surgeons, gastroenter-
ologists, and immunologists, as well as other specialists
depending on the disease location (Callen, 1998). It is a
challenging diagnosis requiring the presence of a classical
clinical presentation with biopsies excluding other important
pathology (Weenig et al., 2002; Brooklyn et al., 2006).
Delayed diagnosis or misdiagnosis can lead to serious
morbidity (Brooklyn et al., 2006).
The epidemiology of PG has never been formally assessed
in a population-based study (Powell et al., 1996). Thus,
estimates of the epidemiology of this disorder are based on
case reports, case series, and cohort studies of individuals
with inflammatory bowel disease (IBD; Farhi et al., 2008;
Vavricka et al., 2011). As a result of these studies, PG has
been estimated to have an incidence rate of 3–10 per million
population per year. Similarly, mortality has been reported in
case reports and case series, with some estimates quoting a
mortality rate of 30% (Saracino et al., 2011). Previous studies
have reported associations with systemic disease in 50% of
cases, most commonly with IBD, rheumatoid arthritis (RA),
and hematological disorders (Powell et al., 1985). PG has
been reported inB2% of individuals with IBD in a variety of
cohorts, but the number of individuals with PG in these large
cohorts is small (n¼ 8 and n¼17; Farhi et al., 2008; Yu¨ksel
et al., 2009). As the epidemiology of PG has never been
formally studied outside the context of IBD, the population-
based incidence, associated mortality, and disease asso-
ciations are unknown. These estimations are critically impor-
tant to enable a better understanding of disease epidemiology,
which is important for planning clinical trials of inter-
ventions, service planning, and education of healthcare
professionals.
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The aims of this study were to determine the incidence
and mortality of PG in the United Kingdom and to assess
what proportion of individuals had associated underlying
systemic disease.
RESULTS
Our cohort included 313 people with incident PG contrib-
uting 1,452 person-years. There were 313 matched general
controls who did not have either RA or IBD, contributing
1,624 person-years, 309 matched RA controls contributing
1,770 person-years, and 303 matched IBD controls con-
tributing 1443 person-years, respectively. The median age at
presentation for PG was 59 (interquartile range 41–72) years,
and 185 (59%) patients were women (Table 1). The median
length of follow-up for individuals with PG was 3.3 years
(interquartile range 1.1–7.5 years). Comorbidity rates, mea-
sured using the Charlson comorbidity index, were higher in
cases compared with general controls, with one or more
comorbidities being present in 43% of cases compared with
only 31% of controls. On examining the components of
the Charlson index, significant differences were observed:
increased rates of uncomplicated diabetes in cases (10%)
compared with controls (3%), increased congestive cardiac
failure (5% compared with 1%), and leukemia in 2% of the
cases and not in controls. There was no significant difference
in overall comorbidity rates compared with IBD controls
(43% compared with 41%) or RA controls (43% in both
groups). On examining the components of the Charlson
index, it was found that leukemia was increased in cases
compared with all control groups (2% vs. 0%), whereas
stroke was increased in IBD controls (6%) compared with
cases (2%).
Validation
Questionnaires were sent to the general practitioners (GPs)
of 80 individuals with diagnoses of PG in the 2 years before
the study end date. Of these, 53 were returned reporting
individuals with ‘‘PG’’ codes; 11 GPs either did not respond
or the response was not valid. Of the 42 cases coded as
‘‘PG’’ for whom we received a valid response, 32 were
confirmed to have a diagnosis of PG (positive predictive
value (PPV) 76%, 95% CI 61–87%). For the 27 questionnaires
Table 1. Demographics of study population
Category
Number
of cases Person-time
Incidence rate (confidence interval) per 100,000 person-years
standardized to European standard population
Overall incidence 313 428.71 0.63 (0.58–0.71)
Incidence by gender
Male 128 211.47 0.55 (0.46–0.65)
Female 185 217.24 0.71 (0.61–0.82)
Incidence by year
1992–1994 39 45.71 0.83 (0.60–1.13)
1995–1997 30 56.90 0.46 (0.33–0.66)
1998–2000 32 75.98 0.37 (0.26–0.53)
2001–2003 61 92.14 0.55 (0.43–0.71)
2004–2006 87 98.09 0.75 (0.61–0.93)
2007–2008 64 59.88 0.90 (0.70–1.15)
Incidence by age category (years) Age-specific incidence rates per 100,000 population
o10 3 47.94 0.06 (0.02–0.19)
10–19 13 50.88 0.26 (0.15–0.44)
20–29 19 53.90 0.35 (0.22–0.55)
30–39 36 65.49 0.55 (0.40–0.76)
40–49 42 62.46 0.66 (0.48–0.89)
50–59 47 54.74 0.86 (0.65–1.14)
60–69 54 42.41 1.27 (0.98–1.66)
70–79 70 31.62 2.25 (1.78–2.83)
80 (maximum) 29 19.28 1.50 (1.04–2.16)
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returned reporting individuals with ‘‘pyoderma’’ codes, we
received 16 valid responses and 8 were confirmed to have a
diagnosis of PG, giving a PPV of 50% (95% CI 26–74%).
Among the confirmed cases with both ‘‘PG’’ and ‘‘pyoder-
ma’’ codes, the majority of GPs reported disease involvement
of the legs in 25 (74%), the trunk in 6 (19%), the arms in
5 (16%), and stomal disease in two patients (6%). A total of
18 GPs (56%) described a rapid onset, and 12 (38%)
described severe pain.
Incidence
The crude overall incidence of PG was 0.73 (95% confidence
interval 0.65–0.82) per 100,000 person-years. On standar-
dizing this rate to the European standard population, the
adjusted incidence rate was found to be 0.63 (95% CI
0.57–0.71) per 100,000 person-years. Incidence increased
with age and was higher in women than in men (Table 1), but
did not vary by calendar region or change over time. We
estimate that the incidence of PG increased 12.13-fold (95%
CI 7.15–20.57) between individuals aged o20 years and
those aged 470 years.
The validation study gave a PPV of 76% for ‘‘PG’’ and
50% for ‘‘pyoderma’’ diagnostic codes. In all, 308 individuals
were identified with ‘‘pyoderma’’ codes. As B50% of these
individuals and 76% of those with ‘‘PG’’ codes are likely to
have PG, the true incidence rate is likely to be closer to 0.91
(95% CI 0.83–1.01) per 100,000 person-years.
Mortality
The risk of death for patients with PG varied according to the
choice of the control group (Table 2)—the risk being three
times higher compared with general population controls
(adjusted hazard ratio¼3.03, 95% CI 1.84–4.73), 74% higher
compared with IBD controls (adjusted hazard ratio¼1.74,
95% CI 1.17–2.59), and only a borderline statistically sign-
ificant increased risk compared with RA controls (adjusted
hazard ratio¼ 1.55, 95% CI 1.01–2.37). On adjusting for
other comorbidities using the Charlson comorbidity index,
the revised hazard compared with general population
controls reduced to 2.87 (95% CI 1.83–4.50), as compared
with 1.64 for IBD controls (95% CI 1.10–2.44), and a revised
hazard of 1.49 compared with RA controls (95% CI
0.96–2.28). The borderline increased significance compared
with that of RA controls disappeared in sensitivity analysis,
excluding cases with leukemia (eight in total, two following
PG) and lymphoma (five in total, two following PG).
Disease associations
Frequently reported disease associations were present in
110 (33%) individuals, the majority having IBD (n¼67;
20.2%), with smaller numbers having RA (n¼39; 11.8%)
and hematological disorders (n¼13; 3.9%), respectively.
Similar disease associations were seen in individuals with
‘‘pyoderma’’ codes, but these were not as strong as those for
individuals with specific codes. No increased association was
seen for osteoarthritis, a disease not previously reported in
association with PG (results not shown).
DISCUSSION
This study identified that PG was associated with significantly
increased mortality rates, three times higher than that for
the general population, almost twice as high as the mortality
in IBD, and a 50% increase compared with that for RA,
although the latter was of borderline significance and
disappeared in sensitivity analysis excluding cases with
leukemia and lymphoma. These results are in contrast with
the disease-specific deaths recorded by the Office for
National Statistics, which recorded only three deaths from
PG in the United Kingdom in 2009. Adjusting for other
comorbidities did not eliminate these increased mortality
rates.
This is a large, population-based study that allows robust
estimation of incidence and mortality and is less susceptible
to selection bias than other study designs. The size of the data
set gives sufficient power to exclude chance as the basis for
the findings and allowed us to undertake the largest study
of pyoderma gangenosum ever undertaken. The use of
routinely collected data indicates that we could not assess
the severity of disease, although it was possible for us to
validate the diagnosis of PG using GP questionnaires.
Table 2. Mortality in pyoderma gangrenosum compared with three control groups
Group Deaths Person-years HR
Adjusted HR
(for age)
Adjusted HR (for
age and gender)
Adjusted HR (for age,
gender, and Charlson
comorbidity index) P-value
General controls without
RA or inflammatory bowel
disease (n=313)
30 1,624 1.0 1.0 1.0 1.0
Cases (n=313) 70 1,452 3.75 (1.98–7.09) 3.03 (1.94–4.73) 3.03 (1.84–4.73) 2.87 (1.83–4.50) o0.001
RA controls (n=309) 35 1,770 1.0 1.0 1.0 1.0
Cases (n=309) 70 1,452 2.31 (1.51–3.51) 1.54 (1.00–2.36) 1.55 (1.01–2.37) 1.48 (0.96–2.28) 0.08
IBD controls (n=302) 40 1,647 1.0 1.0 1.0 1.0
Cases (n=302) 70 1,443 1.97 (1.33–2.93) 1.72 (1.16–2.56) 1.74 (1.17–2.59) 1.64 (1.10–2.44) 0.02
Abbreviations: HR, hazard ratio; IBD, inflammatory bowel disease; RA, rheumatoid arthritis.
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However, opportunities for error in our study do exist. In our
incidence study, although we have taken care to validate the
diagnoses of PG (in effect determining the specificity of our
code list for the diagnosis) and correct our results for the
errors shown, we are unable realistically to provide a precise
estimate of the sensitivity of our code list. Therefore, it is
possible that a number of incident cases of PG have not been
detected and that we have underestimated incidence. Given
that this is a rare diagnosis without multiple alternate names,
which is of great importance to patients and therefore their
GPs, when it is present we think any such error is likely to be
small. Misclassification of PG is always a difficult issue
because it is a diagnosis of exclusion; this issue has been
highlighted in series from tertiary care and may indeed be an
issue for this data source despite our best efforts to validate
the data (Weenig et al., 2002). If some of the PG cases
included are prevalent rather than incident cases, it might
lead to an overestimation of incidence, as well as survival
bias, thus leading to an underestimation of true mortality
rates. Again, we believe that such an error is unlikely to have
had a large effect given the previous validation of the
algorithm used to determine incidence in another chronic
disease (Lewis et al., 2005). Conversely, studies of skin
cancer incidence suggest undercoding and reporting of skin
cancers; hence, true incidence could be higher than our study
estimates (Bath-Hextall et al., 2007).
There are no previous population-based studies of PG.
Previous estimates of the epidemiology of PG have been
based on case reports and case series from tertiary-care
settings and cohort studies involving individuals with IBD
(Powell et al., 1985; Bennett et al., 2000; Bernstein et al.,
2001; Farhi et al., 2008). The estimated incidence usually
quoted in the literature is 3–10 per million population per
year. Our estimated incidence is consistent with these
reports, with an incidence of 6 per million when standardized
to the European standard population, i.e., 0.63 (95% CI
0.57–0.71 per 100,000 person-years). However, the true
incidence rate is likely to be closer to 0.91 (95% CI
0.83–1.01) per 100,000 person-years when accounting for
the PPV of a diagnostic code for ‘‘PG’’ and the fact that
B50% of those with ‘‘pyoderma’’ codes also have PG.
Previous authors have suggested an increased incidence in
women, which is consistent with our study findings (von den
Driesch, 1997). The reasons for this are not clear and may
warrant further study. Mortality rates of up to 30% overall
have been reported in the literature, but there are no
estimates of increases in mortality compared with controls.
In our cohort, 22% of the study population died during the
study, which translates into a 3-fold increased risk compared
with the general age-, sex-, and practice-matched population.
Previous reports from tertiary-care centers have described
association with underlying systemic disease in up to 50% of
those affected. In this study, we have found that 33% of the
study population had underlying IBD, RA, or hematological
disease. Ascertainment bias may have played a role in the
higher number of reported associations in previous studies, as
individuals in a tertiary-care setting may be more likely to be
diagnosed with PG in a setting of concurrent disease, or
equally might be more likely to have minor manifestations of
associated disease or asymptomatic disease investigated once
they are diagnosed with PG.
To our knowledge, there are no previous population-based
cohort studies of PG. It provides useful information on
incidence, mortality rates, the validity of a PG diagnosis in
GPRD, and disease associations, which will be extremely
useful data for planning clinical care and clinical trials. PG
has recently been identified as a top priority for independent
research by the UK Dermatology Clinical trials network
(http://www.ukdctn.org/home/ and http://www.stopgaptrial.
co.uk/).
Our study has shown high mortality associated with PG;
mortality rates were three times higher than those in the
general population, 70% higher than those in individuals
with IBD, and 50% higher than those in age-, gender-, and
practice-matched controls with RA. Factors leading to
increased mortality in these individuals warrant further study.
Previous measures have underestimated the burden of PG, in
terms of risk of death.
MATERIALS AND METHODS
The GPRD is the world’s largest computerized database of
anonymized longitudinal patient records from general practice,
containing data on B8% of the UK population. Data are obtained
from4625 general practices for a currently registered population of
45 million people representative of the general UK population
(General Practice Research Database, 2011). The data contain
complete medical records of these individuals, including prescrip-
tions and feedback from referrals, as well as hospitalizations. The
validity of GPRD data has been widely demonstrated for epidemio-
logical research, including research in IBD (Lewis et al., 2002; Jick
et al., 2003; Herrett et al., 2010).
Study population
Between 1992 and 2008, we identified all patients with a diagnosis
of ‘‘PG’’ from the General Practice Research Database (GPRD) using
diagnostic READ and OXMIS codes (M070200 and 6860GP).
Individuals were also identified with ‘‘pyoderma’’ READ or OXMIS
codes as a sensitivity analysis (M070.00, M070z00, and 6,860). To
exclude prevalent cases, we imposed a lag period of 12 months after
registration with their GP. This method has been previously
validated by Lewis et al. (2005) to differentiate between incident
and prevalent cases of disorders. We selected three control groups
matched 1:1 randomly by age, sex, and general practice: one group
had neither RA nor IBD, the second control group had RA, and the
final group had IBD. Controls also had to be alive and contributing
data to the GPRD on the date of diagnosis of the matched case. We
assigned a date of ‘‘pseudodiagnosis’’ to controls, which was the
date of diagnosis for the matched case.
Validation
A questionnaire was distributed to the GPs of all 80 individuals
with a diagnostic code either for ‘‘PG’’ or ‘‘pyoderma’’ in the past
2 years of the study, who remained active in their practices
to determine whether the individuals had a confirmed diagnosis of
PG and to obtain descriptive data regarding diagnosis and
presentation (Supplementary Material online).
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Outcomes
We recorded incident diagnoses and dates of death. The follow-up
period began on the date of first diagnosis, or the date of
‘‘pseudodiagnosis’’ for controls.
Statistical analysis
Incidence. We calculated incidences by age, categorized into
10-year age bands, sex, and calendar period. We used multivariate
Poisson regression to model incidence rate ratios, adjusting for
changes in age and gender structure over time. Incidence rates were
standardized to the 2,000 European standard population. To provide
the most accurate estimate possible, we also adjusted these rates
for the PPV of a code for PG as established from our validation study.
The impact of including individuals with ‘‘pyoderma’’ codes on the
incidence rates was explored.
Mortality. All deaths in the case population and matched control
groups were identified, and Kaplan–Meier techniques were used to
calculate 1-year mortality and 5-year survival rates. We used Cox
regression to compare the mortality of cases and the three groups of
controls, adjusting for age, sex, and calendar period. We used
Schoenfeld residuals to evaluate the proportional hazards assump-
tion (Hess, 1995). Comorbidity was assessed using the Charlson
comorbidity index to determine whether any observed differences in
mortality related to underlying comorbidity (Charlson et al., 1987).
A sensitivity analysis was undertaken, excluding cases with leukamia
and lymphoma in order to ensure that mortality was not explained
by atypical PG.
Sample size
The size of the study sample was determined by the number of
patients identified with PG in the UK GPRD. The study had about
80% power to detect a relative risk of mortality of 1.5.
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